bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Dense and Nondense Mammographic Area and Risk of Breast Cancer by Age and Tumor Characteristics
Authors: Bertrand Kimberly A. , Scott Christopher G. , Tamimi Rulla M. , Jensen Matthew R. , Pankratz V. Shane , Norman Aaron D. , Visscher Daniel W. , Couch Fergus J. , Shepherd John , Chen Yunn-Yi , Fan Bo , Wu Fang-Fang , Ma Lin , Beck Andrew H. , Cummings Steven R. , Kerlikowske Karla , Vachon Celine M.
Published: April 2023

Abstract
Background: Mammographic density (MD) is a strong breast cancer risk factor. We previously reported associations of percent mammographic density (PMD) with larger and node-positive tumors across all ages, and estrogen receptor (ER)–negative status among women ages <55 years. To provide insight into these associations, we examined the components of PMD [dense area (DA) and nondense area (NDA)] with breast cancer subtypes.

Methods: Data were pooled from six studies including 4,095 breast cancers and 8,558 controls. DA and NDA were assessed from digitized film-screen mammograms and standardized across studies. Breast cancer odds by density phenotypes and age according to histopathologic characteristics and receptor status were calculated using polytomous logistic regression.

Results: DA was associated with increased breast cancer risk [OR for quartiles: 0.65, 1.00 (Ref), 1.22, 1.55; Ptrend <0.001] and NDA was associated with decreased risk [ORs for quartiles: 1.39, 1.00 (Ref), 0.88, 0.72; Ptrend <0.001] across all ages and invasive tumor characteristics. There were significant trends in the magnitude of associations of both DA and NDA with breast cancer by increasing tumor size (Ptrend < 0.001) but no differences by nodal status. Among women <55 years, DA was more strongly associated with increased risk of ER+ versus ER− tumors (Phet = 0.02), while NDA was more strongly associated with decreased risk of ER− versus ER+ tumors (Phet = 0.03).

Conclusions: DA and NDA have differential associations with ER+ versus ER− tumors that vary by age.

Impact: DA and NDA are important to consider when developing age- and subtype-specific risk models. Cancer Epidemiol Biomarkers Prev; 24(5); 798–809. ©2015 AACR.
Data from Estrogen Metabolism and Mammographic Density in Postmenopausal Women: A Cross-Sectional Study
Authors: Fuhrman Barbara J. , Brinton Louise A. , Pfeiffer Ruth M. , Xu Xia , Veenstra Timothy D. , Teter Barbara E. , Byrne Celia , Dallal Cher M. , Barba Maddalena , Muti Paola C. , Gierach Gretchen L.
Published: April 2023

Abstract
Background: Prospective studies have consistently found that postmenopausal breast cancer risk increases with circulating estrogens; however, findings from studies of estrogens and mammographic density (MD), an intermediate marker of breast cancer risk, have been inconsistent. We investigated the cross-sectional associations of urinary estrogens, and their 2-, 4-, and 16-hydroxylated metabolites with MD.

Methods: Postmenopausal women without breast cancer (n = 194), ages 48 to 82 years, and reporting no current menopausal hormone therapy use were enrolled at a clinic in Western NY in 2005. Urinary estrogens and estrogen metabolites were measured using mass spectrometry. Percent MD and dense area (cm2) were measured using computer-assisted analyses of digitized films. Linear regression models were used to estimate associations of log-transformed estrogen measures with MD while adjusting for age, body mass index (BMI), parity, and past hormone therapy use.

Results: Urinary concentrations of most individual estrogens and metabolites were not associated with MD; however, across the interdecile range of the ratio of parent estrogens (estrone and estradiol) to their metabolites, MD increased by 6.8 percentage points (P = 0.02) and dense area increased by 10.3 cm2 (P = 0.03). Across the interdecile ranges of the ratios of 2-, 4-, and 16-hydroxylation pathways to the parent estrogens, MD declined by 6.2 (P = 0.03), 6.4 (P = 0.04), and 5.7 (P = 0.05) percentage points, respectively. All associations remained apparent in models without adjustment for BMI.

Conclusion: In this study of postmenopausal women, less extensive hydroxylation of parent estrogens was associated with higher MD.

Impact: Hydroxylation of estrogens may modulate postmenopausal breast cancer risk through a pathway involving MD. Cancer Epidemiol Biomarkers Prev; 21(9); 1582–91. ©2012 AACR.
Data from Fine-mapping of the 5p15.33, 6p22.1-p21.31, and 15q25.1 Regions Identifies Functional and Histology-Specific Lung Cancer Susceptibility Loci in African-Americans
Authors: Walsh Kyle M. , Gorlov Ivan P. , Hansen Helen M. , Wu Xifeng , Spitz Margaret R. , Zhang Huifeng , Lu Emily Y. , Wenzlaff Angela S. , Sison Jennette D. , Wei Chongjuan , Lloyd Stacy M. , Chen Wei , Frazier Marsha L. , Seldin Michael F. , Bierut Laura J. , Bracci Paige M. , Wrensch Margaret R. , Schwartz Ann G. , Wiencke John K. , Amos Christopher I.
Published: April 2023

Abstract
Background: Genome-wide association studies of European and East Asian populations have identified lung cancer susceptibility loci on chromosomes 5p15.33, 6p22.1-p21.31, and 15q25.1. We investigated whether these regions contain lung cancer susceptibly loci in African-Americans and refined previous association signals by using the reduced linkage disequilibrium observed in African-Americans.

Methods: 1,308 African-American cases and 1,241 African-American controls from 3 centers were genotyped for 760 single-nucleotide polymorphisms (SNP) spanning 3 regions, and additional SNP imputation was carried out. Associations between polymorphisms and lung cancer risk were estimated using logistic regression, stratified by tumor histology where appropriate.

Results: The strongest associations were observed on 15q25.1 in/near CHRNA5, including a missense substitution [rs16969968: OR, 1.57; 95% confidence interval (CI), 1.25–1.97; P, 1.1 × 10−4) and variants in the 5′-UTR. Associations on 6p22.1-p21.31 were histology specific and included a missense variant in BAT2 associated with squamous cell carcinoma (rs2736158: OR, 0.64; 95% CI, 0.48–0.85; P, 1.82 × 10−3). Associations on 5p15.33 were detected near TERT, the strongest of which was rs2735940 (OR, 0.82; 95% CI, 0.73–0.93; P, 1.1 × 10−3). This association was stronger among cases with adenocarcinoma (OR, 0.75; 95% CI, 0.65–0.86; P, 8.1 × 10−5).

Conclusions: Polymorphisms in 5p15.33, 6p22.1-p21.31, and 15q25.1 are associated with lung cancer in African-Americans. Variants on 5p15.33 are stronger risk factors for adenocarcinoma and variants on 6p21.33 associated only with squamous cell carcinoma.

Impact: Results implicate the BAT2, TERT, and CHRNA5 genes in the pathogenesis of specific lung cancer histologies. Cancer Epidemiol Biomarkers Prev; 22(2); 251–60. ©2012 AACR.
Data from Adult Body Size and Physical Activity in Relation to Risk of Breast Cancer According to Tumor Androgen Receptor Status
Authors: Zhang Xuehong , Eliassen A. Heather , Tamimi Rulla M. , Hazra Aditi , Beck Andrew H. , Brown Myles , Collins Laura C. , Rosner Bernard , Hankinson Susan E.
Published: April 2023

Abstract
Background: Obesity and physical activity have been hypothesized to affect breast cancer risk partly via the androgen signaling pathway. We conducted the first study to evaluate these associations by tumor androgen receptor (AR) status.

Methods: Height, weight, and physical activity were assessed using questionnaires in the Nurses' Health Study. AR, estrogen receptor (ER), and progesterone receptor (PR) status were determined using immunohistochemistry on tumor tissue and medical/pathology reports.

Results: A total of 1,701 AR+ and 497 AR− cases were documented during 26 years of follow-up of 103,577 women. After adjusting for ER/PR status and other risk factors, the relative risks (RR) and 95% confidence intervals (95% CI) for every 5 kg/m2 increase in body mass index (BMI) were 1.07 (1.01–1.13) for AR+ and 1.16 (1.05–1.29) for AR− tumors (P-heterogeneity = 0.17). The RRs (95% CIs) per 5 hours of brisk walking/week were 0.87 (0.73–1.04) for AR+ and 0.67 (0.45–0.99) for AR− tumors (P-heterogeneity = 0.22). Further, BMI, but not physical activity, associations differed significantly across ER/PR/AR subtypes (P-heterogeneity = 0.04 and 0.63, respectively). The RRs (95% CIs) for 5 kg/m2 increase in BMI were 1.23 (1.04–1.45) for ER+PR+AR−, 1.19 (1.01–1.39) for ER−PR−AR−, 1.15 (1.08–1.23) for ER+PR+AR+, and 0.88 (0.75–1.03) for ER+PR−AR+ tumors.

Conclusions: Higher BMI was associated with an increased risk of both AR+ and AR− breast tumors in postmenopausal women, whereas physical activity, including brisk walking, was associated with a reduced risk of both subtypes. In addition, a significant positive association was observed between higher BMI and ER−PR−AR− tumors.

Impact: The similar associations observed by AR status suggest that mechanisms other than androgen signaling underlie these two breast cancer risk factors. Cancer Epidemiol Biomarkers Prev; 24(6); 962–8. ©2015 AACR.
Data from Impact of Sixteen Established Pancreatic Cancer Susceptibility Loci in American Jews
Authors: Streicher Samantha A. , Klein Alison P. , Olson Sara H. , Amundadottir Laufey T. , DeWan Andrew T. , Zhao Hongyu , Risch Harvey A.
Published: April 2023

Abstract
Background: The higher risk of pancreatic cancer in Ashkenazi Jews compared with non-Jews is only partially explained by the increased frequency of BRCA1 and BRCA2 mutations in Ashkenazi Jews.

Methods: We evaluated the impact of 16 established pancreatic cancer susceptibility loci in a case–control sample of American Jews, largely Ashkenazi, including 406 full-Jewish pancreatic cancer patients and 2,332 full-Jewish controls, genotyped as part of the Pancreatic Cancer Cohort and Case–Control Consortium I/II (PanScan I/II), Pancreatic Cancer Case-Control Consortium (PanC4), and Resource for Genetic Epidemiology Research on Adult Health and Aging (GERA) datasets. We compared risk in full-Jewish subjects with risk in part-Jewish; non-Jewish Southern European; and in the combined non-Jewish Eastern, Northern, Southern, and Western European (non-Jewish white European) subjects from the same datasets. Jewish ancestries were genetically identified using seeded Fast principal component analysis. Data were analyzed by unconditional logistic regression, and adjusted for age, sex, and principal components.

Results: One SNP on chromosome 13q22.1 (rs9543325; OR, 1.36; 95% confidence interval, 1.16–1.58; P = 10−4.1) was significant in full-Jews. Individual ORs and minor allele frequencies were similar between Jewish and non-Jewish white European subjects. The average ORs across the 16 pancreatic cancer susceptibility loci for full-Jewish, full- plus part-Jewish, non-Jewish Southern European, and non-Jewish white European subjects were 1.25, 1.30, 1.31, and 1.26, respectively.

Conclusions: The 16 pancreatic cancer susceptibility loci similarly impact Jewish and non-Jewish white European subjects, both individually and as summary odds.

Impact: These 16 pancreatic cancer susceptibility loci likely do not explain the higher risk seen in Ashkenazi Jews. Cancer Epidemiol Biomarkers Prev; 26(10); 1540–8. ©2017 AACR.
Data from Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non–Small Cell Lung Cancer: A Meta-analysis
Authors: Qiu Mantang , Wang Jie , Xu Youtao , Ding Xiangxiang , Li Ming , Jiang Feng , Xu Lin , Yin Rong
Published: April 2023

Abstract
Background: Circulating tumor DNA (ctDNA) has offered a minimally invasive and feasible approach for detection of EGFR mutation for non–small cell lung cancer (NSCLC). This meta-analysis was designed to investigate the diagnostic value of ctDNA, compared with current “gold standard,” tumor tissues.

Methods: We searched PubMed, EMBASE, Cochrane Library, and Web of Science to identify eligible studies that reported the sensitivity and specificity of ctDNA for detection of EGFR mutation status in NSCLC. Eligible studies were pooled to calculate the pooled sensitivity, specificity, and diagnostic odds ratio (DOR). The summary ROC curve (SROC) and area under SROC (AUSROC) were used to evaluate the overall diagnostic performance.

Results: Twenty-seven eligible studies involving 3,110 participants were included and analyzed in our meta-analysis, and most studies were conducted among Asian population. The pooled sensitivity, specificity, and DOR were 0.620 [95% confidence intervals (CI), 0.513–0.716), 0.959 (95% CI, 0.929–0.977), and 38.270 (95% CI, 21.090–69.444), respectively. The AUSROC was 0.91 (95% CI, 0.89–0.94), indicating the high diagnostic performance of ctDNA.

Conclusion: ctDNA is a highly specific and effective biomarker for the detection of EGFR mutation status.

Impact: ctDNA analysis will be a key part of personalized cancer therapy of NSCLC. Cancer Epidemiol Biomarkers Prev; 24(1); 206–12. ©2014 AACR.
Supplementary Figure 1 from Targeting the Phosphoinositide 3-Kinase p110-α Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer
Authors: Wojtalla Anna , Fischer Barbara , Kotelevets Nataliya , Mauri Francesco A. , Sobek Jens , Rehrauer Hubert , Wotzkow Carlos , Tschan Mario P. , Seckl Michael J. , Zangemeister-Wittke Uwe , Arcaro Alexandre
Published: April 2023

PDF file - 1030K, PI3K inhibition blocks SCLC cell viability and PI3K downstream signaling
Supplementary Figures from Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance
Authors: Ye Zhenqing , Dong Haidong , Li Ying , Ma Tao , Huang Haojie , Leong Hon Sing , Eckel-Passow Jeanette , Kocher Jean-Pierre A. , Liang Han , Wang Liguo
Published: April 2023

Figure S1-S8
Supplementary Table 4 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
Authors: Magrangeas Florence , Kuiper Rowan , Avet-Loiseau Hervé , Gouraud Wilfried , Guérin-Charbonnel Catherine , Ferrer Ludovic , Aussem Alexandre , Elghazel Haytham , Suhard Jérôme , Der Sakissian Henri , Attal Michel , Munshi Nikhil C. , Sonneveld Pieter , Dumontet Charles , Moreau Philippe , van Duin Mark , Campion Loïc , Minvielle Stéphane
Published: April 2023

Supplementary Table 4: Candidate Gene SNPs in the IFM cohort
Supplementary Figures from The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome
Authors: Ricciardelli Carmela , Bianco-Miotto Tina , Jindal Shalini , Butler Lisa M. , Leung Samuel , McNeil Catriona M. , O'Toole Sandra A. , Ebrahimie Esmaeil , Millar Ewan K.A. , Sakko Andrew J. , Ruiz Alexandra I. , Vowler Sarah L. , Huntsman David G. , Birrell Stephen N. , Sutherland Robert L. , Palmieri Carlo , Hickey Theresa E. , Tilley Wayne D.
Published: April 2023

Supplementary Figures 1-3
Revised Supplementary Tables from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Authors: Mercogliano María F. , De Martino Mara , Venturutti Leandro , Rivas Martín A. , Proietti Cecilia J. , Inurrigarro Gloria , Frahm Isabel , Allemand Daniel H. , Deza Ernesto Gil , Ares Sandra , Gercovich Felipe G. , Guzmán Pablo , Roa Juan C. , Elizalde Patricia V. , Schillaci Roxana
Published: April 2023

Supplementary Table S1. Patient baseline characteristics. Supplementary Table S2. Growth rate of TNFα-producing and control BT-474 tumors treated with trastuzumab
Revised Supplementary Data from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Authors: Mercogliano María F. , De Martino Mara , Venturutti Leandro , Rivas Martín A. , Proietti Cecilia J. , Inurrigarro Gloria , Frahm Isabel , Allemand Daniel H. , Deza Ernesto Gil , Ares Sandra , Gercovich Felipe G. , Guzmán Pablo , Roa Juan C. , Elizalde Patricia V. , Schillaci Roxana
Published: April 2023

Revised Supplementary Data
Supplemental Legends from Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes
Authors: Mohme Malte , Schliffke Simon , Maire Cecile L. , Rünger Alessandra , Glau Laura , Mende Klaus C. , Matschke Jakob , Gehbauer Christina , Akyüz Nuray , Zapf Svenja , Holz Mareike , Schaper Miriam , Martens Tobias , Schmidt Nils O. , Peine Sven , Westphal Manfred , Binder Mascha , Tolosa Eva , Lamszus Katrin
Published: April 2023

Supplementary Figure and Table Legends
Suppl. Tables 1-3 from Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes
Authors: Mohme Malte , Schliffke Simon , Maire Cecile L. , Rünger Alessandra , Glau Laura , Mende Klaus C. , Matschke Jakob , Gehbauer Christina , Akyüz Nuray , Zapf Svenja , Holz Mareike , Schaper Miriam , Martens Tobias , Schmidt Nils O. , Peine Sven , Westphal Manfred , Binder Mascha , Tolosa Eva , Lamszus Katrin
Published: April 2023

Supplemental Table 1. Patient characteristics for flow-cytometry analysis. IDH=isocitrate dehydrogenase, MGMT=O6-Methylguanin-DNA-Methyltransferase. Supplemental Table 2. Matched-paired GBM patient samples for TCR repertoire sequencing analysis. T=radiotherapy, CT=chemotherapy with temozolomide Supplemental Table 3. Antibodies used to polychromatic flow-cytometry analysis of T-cells
Supplementary Table 1-3 from Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer
Authors: Xu Chang , Nikolova Olga , Basom Ryan S. , Mitchell Ryan M. , Shaw Reid , Moser Russell D. , Park Heuijoon , Gurley Kay E. , Kao Michael C. , Green Carlos L. , Schaub Franz X. , Diaz Robert L. , Swan Hallie A. , Jang In S. , Guinney Justin , Gadi Vijayakrishna K. , Margolin Adam A. , Grandori Carla , Kemp Christopher J. , Méndez Eduardo
Published: April 2023

Supplementary Table 1, 2, 3
Supplementary Figure Legends from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
Authors: Dettling Steffen , Stamova Slava , Warta Rolf , Schnölzer Martina , Rapp Carmen , Rathinasamy Anchana , Reuss David , Pocha Kolja , Roesch Saskia , Jungk Christine , Warnken Uwe , Eckstein Volker , Grabe Niels , Schramm Christoph , Weigand Markus A. , von Deimling Andreas , Unterberg Andreas , Beckhove Philipp , Herold-Mende Christel
Published: April 2023

Supplementary Figure Legends
Suppl. Table 1, 3-8 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
Authors: Dettling Steffen , Stamova Slava , Warta Rolf , Schnölzer Martina , Rapp Carmen , Rathinasamy Anchana , Reuss David , Pocha Kolja , Roesch Saskia , Jungk Christine , Warnken Uwe , Eckstein Volker , Grabe Niels , Schramm Christoph , Weigand Markus A. , von Deimling Andreas , Unterberg Andreas , Beckhove Philipp , Herold-Mende Christel
Published: April 2023

Clinical data of IDHmut LGG patients
Legends of supplementary figures from Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring
Authors: Guffroy Magali , Falahatpisheh Hadi , Biddle Kathleen , Kreeger John , Obert Leslie , Walters Karen , Goldstein Richard , Boucher Germaine , Coskran Timothy , Reagan William , Sullivan Danielle , Huang Chunli , Sokolowski Sharon , Giovanelli Richard , Gerber Hans-Peter , Finkelstein Martin , Khan Nasir
Published: April 2023

Legends of supplementary figures 1, 2 and 3
Suppl. Figure 3 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
Authors: Dettling Steffen , Stamova Slava , Warta Rolf , Schnölzer Martina , Rapp Carmen , Rathinasamy Anchana , Reuss David , Pocha Kolja , Roesch Saskia , Jungk Christine , Warnken Uwe , Eckstein Volker , Grabe Niels , Schramm Christoph , Weigand Markus A. , von Deimling Andreas , Unterberg Andreas , Beckhove Philipp , Herold-Mende Christel
Published: April 2023

(A) Significantly increased immune responses in IDHmut lower-grade glioma patients (P) vs. healthy donors (HD) seen for the potential T-cell target antigens CRKII, CFL1, CNTN1, NME2, and TKT. Homogenous levels of stimulation while comparing IFN-ð�›¾ spot numbers among astrocytomas (red) and oligodendrogliomas (blue) to a certain TAA as well as (B) the total immune response. (C) IFN-ð�›¾ ELISpot raw data showing the spot count / 1x105 T-cells upon stimulation with autologous dendritic cells loaded with antigens (CRKII, CFL1, CNTN1, NME2, or TKT, black bar) vs. negative control (IgG1, grey bar) for each patient (P) (n = 16). Highlighted in green: significant immune responses (p < 0.05) with an > 2-fold increased spot count compared to the negative control (IgG) (*, p < 0.05; **, p < 0.01; ***, p < 0.001)
Supplementary Figure Legend from miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5
Authors: Stiegelbauer Verena , Vychytilova-Faltejskova Petra , Karbiener Michael , Pehserl Anna-Maria , Reicher Andreas , Resel Margit , Heitzer Ellen , Ivan Cristina , Bullock Marc , Ling Hui , Deutsch Alexander , Wulf-Goldenberg Annika , Adiprasito Jan Basri , Stoeger Herbert , Haybaeck Johannes , Svoboda Marek , Stotz Michael , Hoefler Gerald , Slaby Ondrej , Calin George Adrian , Gerger Armin , Pichler Martin
Published: April 2023

Supplementary Figure Legend
Supporting Information from Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis
Authors: Bartolomé Rubén A. , Aizpurua Carmen , Jaén Marta , Torres Sofía , Calviño Eva , Imbaud Juan I. , Casal J. Ignacio
Published: April 2023

Supplementary Methodology Legends to supplementary figures
FcRn-mediated transcytosis and transport of Fc-fused IL-7 into serum after intravaginal treatment from Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells
Authors: Choi Young Woo , Kang Moon Cheol , Seo Yong Bok , Namkoong Hong , Park Yunji , Choi Dong-Hoon , Suh You Suk , Lee Seung-Woo , Sung Young Chul , Jin Hyun-Tak
Published: April 2023

Supplementary Figure 2. FcRn-mediated transcytosis and transport of Fc-fused IL-7 into serum after intravaginal treatment
Distinct localization patterns of CD4 and CD8 T cells after intravaginal administration of IL-7-Fc from Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells
Authors: Choi Young Woo , Kang Moon Cheol , Seo Yong Bok , Namkoong Hong , Park Yunji , Choi Dong-Hoon , Suh You Suk , Lee Seung-Woo , Sung Young Chul , Jin Hyun-Tak
Published: April 2023

Supplementary Figure 3. Distinct localization patterns of CD4 and CD8 T cells after intravaginal administration of IL-7-Fc
supplementary Table S4 from BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Authors: Barras David , Missiaglia Edoardo , Wirapati Pratyaksha , Sieber Oliver M. , Jorissen Robert N. , Love Chris , Molloy Peter L. , Jones Ian T. , McLaughlin Stephen , Gibbs Peter , Guinney Justin , Simon Iris M. , Roth Arnaud D. , Bosman Fred T. , Tejpar Sabine , Delorenzi Mauro
Published: April 2023

Genes that characterize the difference between BM1 and BM2 (BM subtypes), MSI and MSS (MSI status), and males and females (gender).
Supplemental Figure 5 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Authors: Ozawa Hiroyuki , Ranaweera Ruchira S. , Izumchenko Evgeny , Makarev Eugene , Zhavoronkov Alex , Fertig Elana J. , Howard Jason D. , Markovic Ana , Bedi Atul , Ravi Rajani , Perez Jimena , Le Quynh-Thu , Kong Christina S. , Jordan Richard C. , Wang Hao , Kang Hyunseok , Quon Harry , Sidransky David , Chung Christine H.
Published: April 2023

Matrigel colony formation assay of FaDu-mock and FaDu-SMAD4 cells treated with PBS or Cetuximab in combination with JNKi (SP600125) or MEKi (U0126) at indicated concentrations for 7 days. (*p<0.05 and **p<0.01 compared to FaDu-mock and FaDu-SMAD4 without MAPK/JNK inhibitor).
Supplementary Figure 3 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
Authors: Panek Rafal , Welsh Liam , Baker Lauren C.J. , Schmidt Maria A. , Wong Kee H. , Riddell Angela M. , Koh Dow-Mu , Dunlop Alex , Mcquaid Dualta , d'Arcy James A. , Bhide Shreerang A. , Harrington Kevin J. , Nutting Christopher M. , Hopkinson Georgina , Richardson Cheryl , Box Carol , Eccles Suzanne A. , Leach Martin O. , Robinson Simon P. , Newbold Kate L.
Published: April 2023

Scatter plots comparing individual MRI measurements (tumor volume, baseline R2* and percentage of fluctuating volume) against pathology (Hoechst 33342 uptake for perfusion, pimonidazole adduct formation for hypoxia) determined from the cohort of CALR xenografts.
Supplemental Figure S7 from ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet–associated Colon Cancer
Authors: Mustafi Reba , Dougherty Urszula , Mustafi Devkumar , Ayaloglu-Butun Fatma , Fletcher Michelle , Adhikari Sarbani , Sadiq Farhana , Meckel Katherine , Haider Haider I. , Khalil Abdurahman , Pekow Joel , Konda Vani , Joseph Loren , Hart John , Fichera Alessandro , Li Yan Chun , Bissonnette Marc
Published: April 2023

Adenomas and adjacent intestinal mucosa from Apc mutant Min mice were probed for pro-TNFÎ±.
Supplemental Figure S1 and Figure S2 from ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet–associated Colon Cancer
Authors: Mustafi Reba , Dougherty Urszula , Mustafi Devkumar , Ayaloglu-Butun Fatma , Fletcher Michelle , Adhikari Sarbani , Sadiq Farhana , Meckel Katherine , Haider Haider I. , Khalil Abdurahman , Pekow Joel , Konda Vani , Joseph Loren , Hart John , Fichera Alessandro , Li Yan Chun , Bissonnette Marc
Published: April 2023

Fig S1. BMS566394 inhibits EGFR signaling in CXCL12 treated HCT116 cells; Fig S2. Schema for CXCL12-CXCR4 transactivation of colon cancer cell EGFR. Shown in the figure are inhibitors or antibodies used in this study: AMD3100 blocks CXCR4; BMS566394 blocks ADAM17 and INCB3619 blocks ADAM17 and ADAM10; C225 antibodies block ligand binding to EGFR.
Figure S3 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Authors: Siemeister Gerhard , Mengel Anne , Fernández-Montalván Amaury E. , Bone Wilhelm , Schröder Jens , Zitzmann-Kolbe Sabine , Briem Hans , Prechtl Stefan , Holton Simon J. , Mönning Ursula , von Ahsen Oliver , Johanssen Sandra , Cleve Arwed , Pütter Vera , Hitchcock Marion , von Nussbaum Franz , Brands Michael , Ziegelbauer Karl , Mumberg Dominik
Published: April 2023

Cell cycle analyses
Supplementary methods and Figure Legends from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Authors: Weigelt Britta , Comino-Méndez Iñaki , de Bruijn Ino , Tian Lei , Meisel Jane L. , García-Murillas Isaac , Fribbens Charlotte , Cutts Ros , Martelotto Luciano G. , Ng Charlotte K.Y. , Lim Raymond S. , Selenica Pier , Piscuoglio Salvatore , Aghajanian Carol , Norton Larry , Murali Rajmohan , Hyman David M. , Borsu Laetitia , Arcila Maria E. , Konner Jason , Reis-Filho Jorge S. , Greenberg Roger A. , Robson Mark E. , Turner Nicholas C.
Published: April 2023

Supplementary Methods and Figure Legends
Sup Fig 1 from Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy
Authors: Karnes R. Jeffrey , Sharma Vidit , Choeurng Voleak , Ashab Hussam Al-Deen , Erho Nicholas , Alshalalfa Mohammed , Trock Bruce , Ross Ashley , Yousefi Kasra , Tsai Harrison , Zhao Shuang G. , Tosoian Jeffrey J. , Haddad Zaid , Takhar Mandeep , Chang S. Laura , Spratt Daniel E. , Abdollah Firas , Jenkins Robert B. , Klein Eric A. , Nguyen Paul L. , Dicker Adam P. , Den Robert B. , Davicioni Elai , Feng Felix Y. , Lotan Tamara L. , Schaeffer Edward M.
Published: April 2023

Figure S1: Functional network of the 84 ADT-RS genes, with significant interaction with ADT, revealing high degree of connectivity for some ADT-RS genes like REST and EZH2, and several pathways potentially involved in ADT resistance mechanism. SOX2 and NANOG are key transcription factors regulating many ADT-RS genes.
Table S1 from Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy
Authors: Orillion Ashley , Damayanti Nur P. , Shen Li , Adelaiye-Ogala Remi , Affronti Hayley , Elbanna May , Chintala Sreenivasulu , Ciesielski Michael , Fontana Luigi , Kao Chinghai , Elzey Bennett D. , Ratliff Timothy L. , Nelson David E. , Smiraglia Dominic , Abrams Scott I. , Pili Roberto
Published: April 2023

List of chemokines/cytokines altered with PR/MR
FigureS2 from Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)
Authors: Garlan Fanny , Laurent-Puig Pierre , Sefrioui David , Siauve Nathalie , Didelot Audrey , Sarafan-Vasseur Nasrin , Michel Pierre , Perkins Geraldine , Mulot Claire , Blons Hélène , Taieb Julien , Di Fiore Frederic , Taly Valerie , Zaanan Aziz
Published: April 2023

Supplementary Figure 2. Impact of baseline ctDNA concentration on overall survival (OS) in the subgroup of patients with ctDNA detectable at baseline (n=63).
Supplementary Figure 2 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Authors: Shah Manish A. , Starodub Alexander , Sharma Sunil , Berlin Jordan , Patel Manish , Wainberg Zev A. , Chaves Jorge , Gordon Michael , Windsor Kevin , Brachmann Carrie Baker , Huang Xi , Vosganian Greg , Maltzman Julia D. , Smith Victoria , Silverman Jeffrey A. , Lenz Heinz-Josef , Bendell Johanna C.
Published: April 2023

Efficacy summary for patients with gastric/GEJ adenocarcinoma (Part B).
Table S1-S4 from Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous Ovarian Cancer and Predicts Differential Therapeutic Responses
Authors: Hao Dapeng , Li Jingjing , Jia Shanshan , Meng Yuan , Zhang Chao , Wang Li , Di Li-jun
Published: April 2023

Table S1-S4
Supplementary Figures and Text from Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors
Authors: Dhawan Mallika S. , Bartelink Imke H. , Aggarwal Rahul Raj , Leng Jim , Zhang Jenna Z. , Pawlowska Nela , Terranova-Barberio Manuela , Grabowsky Jennifer A. , Gewitz Andrew , Chien Amy J. , Moasser Mark , Kelley Robin K. , Maktabi Tayeba , Thomas Scott , Munster Pamela N.
Published: April 2023

Supplementary table 1 Observed and predicted blood toxicity profile at the start of Cycle 2 and Cycle 4 (A) and PK-toxicity model-predicted (B) neutrophil and platelet toxicity at cycle 2, day 1 and cycle 5 talozaparib 1mg/carboplatin AUC 1/5 weekly dosing: Absolute change from baseline. Supplementary Table 2: PK toxicity model estimates Supplementary Figure 1a: Goodness of fit plots of all modeled PK and PK-toxicity data. Supplementary Figure 2 Talazoparib drug clearance in gBRCA carriers versus non-carriers of talazoparib Supplementary table 3 Simulated blood toxicity profile of new dosing regimens using the PK-toxicity model. A) planned schedule B) optimized talazoparib, C) optimized carboplatin, D) optimized combination E) simulation of single agent toxicity.
Supplementary tables and figures from Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer
Authors: Feng Yan , Wang Xiaoning , Bajaj Gaurav , Agrawal Shruti , Bello Akintunde , Lestini Brian , Finckenstein Friedrich Graf , Park Jong-Soon , Roy Amit
Published: April 2023

Supplementary Table S1. Summary of clinical studies included in the E-R analyses Supplementary Table S2. Model-estimated HR of death (relative to median Cavg1 at 3 mg/kg: 26.9 µg/mL) Supplementary Figure S1. Kaplan-Meier plot of OS in NSCLC by tertile of Cavg1 at (A) 3 mg/kg and (B) 10 mg/kg. Both squamous and non-squamous data were pooled for the Kaplan-Meier analysis. Within-dose E-R relationships were observed for both the (A) 3 mg/kg dose and (B) the 10 mg/kg dose, indicating that factors other than exposure impacted OS. Abbreviations: NSCLC: non-small cell lung cancer; OS: overall survival. Supplementary Figure S2. Kaplan-Meier plot of OS in squamous NSCLC by Cavg1 tertile at a given tertile of baseline clearance; (A) first tertile of baseline clearance and tertile of Cavg1, (B) second tertile of baseline clearance and tertile of Cavg1, and (C) third tertile of baseline clearance and tertile of Cavg1. Exposure was not associated with OS in squamous NSCLC after accounting for the clearance effect, as patients with a higher exposure (red line) appeared to have a reduced or similar clearance effect in comparison with patients with lower exposure (green line). Abbreviations: BCL, baseline clearance; NSCLC: non-small cell lung cancer; T, tertile. Supplementary Figure S3. Kaplan-Meier plot of OS in non-squamous NSCLC by Cavg1 tertile at a given tertile of baseline clearance; (A) first tertile of baseline clearance and tertile of Cavg1, (B) second tertile of baseline clearance and tertile of Cavg1, and (C) third tertile of baseline clearance and tertile of Cavg1. Exposure was not associated with OS in non-squamous NSCLC after accounting for the clearance effect, as patients with higher exposure (blue line) appeared to have a reduced clearance effect in comparison with patients with lower exposure (red line). Abbreviations: Cavg1, model-predicted time-averaged steady-state concentration; BCL, baseline clearance; NSCLC: non-small cell lung cancer; OS, overall survival; T, tertile. Supplementary Figure S4. Kaplan-Meier plot of (A) any-cause grade {greater than or equal to}3 AEs by dose and (B) treatment-related grade {greater than or equal to}3 AEs by dose (B). There was no apparent relationship between dose level and these safety endpoints. Abbreviations: AEs, adverse events.
Supplementary table 6 from Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and MUTYH-associated Polyposis
Authors: Thomas Laura E. , Hurley Joanna J. , Meuser Elena , Jose Sian , Ashelford Kevin E. , Mort Matthew , Idziaszczyk Shelley , Maynard Julie , Brito Helena Leon , Harry Manon , Walters Angharad , Raja Meera , Walton Sarah-Jane , Dolwani Sunil , Williams Geraint T. , Morgan Meleri , Moorghen Morgan , Clark Susan K. , Sampson Julian R.
Published: April 2023

Sequencing metrics for all adenomas and matched blood samples that were subjected to exome sequencing.
Figure S1 from Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/β-Catenin Signaling
Authors: Wang Guangzhi , Shen Jia , Sun Jiahang , Jiang Zhenfeng , Fan Jiabing , Wang Hongjun , Yu Shan , Long Yu , Liu Yi , Bao Hongbo , Zhang Kelvin Xi , Han Ke , Zhu Minwei , Zheng Yongri , Lin Zhiguo , Jiang Chuanlu , Guo Mian
Published: April 2023

Supplementary methods and figure legends
Supplementary methods from Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and MUTYH-associated Polyposis
Authors: Thomas Laura E. , Hurley Joanna J. , Meuser Elena , Jose Sian , Ashelford Kevin E. , Mort Matthew , Idziaszczyk Shelley , Maynard Julie , Brito Helena Leon , Harry Manon , Walters Angharad , Raja Meera , Walton Sarah-Jane , Dolwani Sunil , Williams Geraint T. , Morgan Meleri , Moorghen Morgan , Clark Susan K. , Sampson Julian R.
Published: April 2023

Supplementary methods
Supplementary_Methods from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo
Authors: Morrow James J. , Mendoza Arnulfo , Koyen Allyson , Lizardo Michael M. , Ren Ling , Waybright Timothy J. , Hansen Ryan J. , Gustafson Daniel L. , Zhou Ming , Fan Timothy M. , Scacheri Peter C. , Khanna Chand
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure S6: Ipilimumab does not deplete CD4+CTLA-4+FOXP3+ Tregs from Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Authors: Sharma Anu , Subudhi Sumit K. , Blando Jorge , Scutti Jorge , Vence Luis , Wargo Jennifer , Allison James P. , Ribas Antoni , Sharma Padmanee
Published: April 2023

Tumor infiltrating cells from paired melanoma tissue (N=5 pre-Ipi; N=5 post-Ipi) were analyzed by CyTOF. The impact of ipilimumab on the intratumoral frequency of A) CD3+CD4+FOXP3+CTLA-4+ (Tregs), B) CD3+CD4+FOXP3-CTLA-4+ T cells, and C) CD3+CD4+FOXP3-CTLA-4- T cells. The dot plots represent mean with SD, and each dot represents a patient. Statistical significance is defined as P< 0.05.
Supplementary Figure 3 from Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
Authors: Horikawa Naoki , Abiko Kaoru , Matsumura Noriomi , Hamanishi Junzo , Baba Tsukasa , Yamaguchi Ken , Yoshioka Yumiko , Koshiyama Masafumi , Konishi Ikuo
Published: April 2023

Expression analysis of ID8-Vegf cells
Descriptions for supplementary data from Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
Authors: Horikawa Naoki , Abiko Kaoru , Matsumura Noriomi , Hamanishi Junzo , Baba Tsukasa , Yamaguchi Ken , Yoshioka Yumiko , Koshiyama Masafumi , Konishi Ikuo
Published: April 2023

Descriptions for supplementary figures and tables
Supplementary Figures 1-13 from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma
Authors: Rojas Elizabeta A. , Corchete Luis Antonio , San-Segundo Laura , Martínez-Blanch Juan F. , Codoñer Francisco M. , Paíno Teresa , Puig Noemí , García-Sanz Ramón , Mateos María Victoria , Ocio Enrique M. , Misiewicz-Krzeminska Irena , Gutiérrez Norma C.
Published: April 2023

Figure S1. (A) Protein expression of p53 in MM cell lines.; Figure S2. (A) Melphalan resistant MM cell line RPMI-LR5 (panel left) and dexamethasone resistant MM cell line MM1R (panel right) were treated with the indicated doses of amiloride for 24, 48 and 72 h, and cell viability was analyzed by CellTiter-Glo luminescent assays; respectively. Figure S3. (A) MM1S-luc cells were treated for 48 hours with the indicated concentrations of amiloride in the presence or absence of MSCs derived from newly-diagnosed (ND) and relapsed/refractory (RR) MM patients, and proliferation was analyzed by bioluminescence (photons/sec). Figure S4. Amiloride induced apoptosis in MM cells. Figure S5. Amiloride did not induce changes in the cell cycle profile of MM cells. Figure S6. Amiloride deregulated mitochondrial potential in MM cells. Figure S7. Activity of amiloride through caspase-dependent and independent mechanisms. Figure S8. The triple and double combination of dexamethasone and melphalan with amiloride displayed superior anti-MM activity and improved median survival compared with single agents and double combinations in a subcutaneous plasmacytoma model. Figure S9. Experimental design for RNA-Seq assay. Figure S10. Pathway enrichment analysis at gene level and differential transcript isoforms expression. Figure S12. Validation of gene expression. Figure S13. Validation of p53 pathway activation in patient cells.
Supplemental Table S4. from The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis
Authors: Stover Daniel G. , Coloff Jonathan L. , Barry William T. , Brugge Joan S. , Winer Eric P. , Selfors Laura M.
Published: April 2023

Percent Pathologic Complete Response by Proliferation Score
Supplemental Figure 7 from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Authors: Doostan Iman , Karakas Cansu , Kohansal Mehrnoosh , Low Kwang-Hui , Ellis Matthew J. , Olson John A. , Suman Vera J. , Hunt Kelly K. , Moulder Stacy L. , Keyomarsi Khandan
Published: April 2023

LMW-E expression in tumor xenografts.
Supplementary Figure S2 from Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer
Authors: Duran Rafael , Mirpour Sahar , Pekurovsky Vasily , Ganapathy-Kanniappan Shanmugasundaram , Brayton Cory F. , Cornish Toby C. , Gorodetski Boris , Reyes Juvenal , Chapiro Julius , Schernthaner Rüdiger E. , Frangakis Constantine , Lin MingDe , Sun Jessica D. , Hart Charles P. , Geschwind Jean-François
Published: April 2023

Supplementary Figure S2: Liver function tests changes after hepatic intraarterial therapy. Liver chemistry (alanine aminotransferase [ALT]
Table 1 from ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Authors: Li Qiang , Damish Alexis W. , Frazier Zoë , Liu David , Reznichenko Elizaveta , Kamburov Atanas , Bell Andrew , Zhao Huiyong , Jordan Emmet J. , Gao S. Paul , Ma Jennifer , Abbosh Philip H. , Bellmunt Joaquim , Plimack Elizabeth R. , Lazaro Jean-Bernard , Solit David B. , Bajorin Dean , Rosenberg Jonathan E. , D'Andrea Alan D. , Riaz Nadeem , Van Allen Eliezer M. , Iyer Gopa , Mouw Kent W.
Published: April 2023

Table 1
Supplemental Table 3 from Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Authors: Offin Michael , Rizvi Hira , Tenet Megan , Ni Andy , Sanchez-Vega Francisco , Li Bob T. , Drilon Alexander , Kris Mark G. , Rudin Charles M. , Schultz Nikolaus , Arcila Maria E. , Ladanyi Marc , Riely Gregory J. , Yu Helena , Hellmann Matthew D.
Published: April 2023

EGFR-TKI resistance mechanisms by TMB tertile
Table S2 from A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Authors: Evans Kurt W. , Yuca Erkan , Akcakanat Argun , Scott Stephen M. , Arango Natalia Paez , Zheng Xiaofeng , Chen Ken , Tapia Coya , Tarco Emily , Eterovic Agda K. , Black Dalliah M. , Litton Jennifer K. , Yap Timothy A. , Tripathy Debu , Mills Gordon B. , Meric-Bernstam Funda
Published: April 2023

Clinically Relevant Alterations
Supplementary File 4 from A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Authors: Paik Paul K. , Shen Ronglai , Berger Michael F. , Ferry David , Soria Jean-Charles , Mathewson Alastair , Rooney Claire , Smith Neil R. , Cullberg Marie , Kilgour Elaine , Landers Donal , Frewer Paul , Brooks Nigel , André Fabrice
Published: April 2023

Treatment history for each patient where available
Supplemental Data from The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma
Authors: Lowery Caitlin D. , VanWye Alle B. , Dowless Michele , Blosser Wayne , Falcon Beverly L. , Stewart Julie , Stephens Jennifer , Beckmann Richard P. , Bence Lin Aimee , Stancato Louis F.
Published: April 2023

Supplemental Table 1. Cell culture conditions. Supplemental Table 2. Antibody details. Supplemental Table 3. Catalog information for Dharmacon RNAi constructs. Supplemental Table 4. EC50 values of prexasertib in pediatric cell lines included in the cancer cell line sensitivity panel. Supplemental Table 5. Quantification of percent positive cells for each immunostain following prexasertib treatment. Supplemental Figure 1. Prexasertib induces caspase activation in NB cell lines. Supplemental Figure 2. Prexasertib promotes neuroblastoma cell death by inducing DNA damage. Supplemental Figure 3. Inhibition of CHK1 promotes phosphorylation of RPA32/2. Supplemental Figure 4. Assessment of siRNA-mediated knockdown of CHK1 on total protein and phosphorylation status. Supplemental Figure 5. No significant weight loss was observed during prexasertib treatment. Supplemental Figure 6. Combination with doxorubicin does not enhance prexasertib efficacy in vivo. Supplemental Figure 7. Vasculature markers are more prevalent in prexasertib-treated neuroblastoma xenografts. Supplemental Figure 8. Prexasertib reduces VEGF endothelial cell cord formation in vitro, but does not affect established cords. Supplemental Figure 9. Neuroblastoma cell lines drive endothelial cord formation in vitro.
Supplementary Figure 3 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Authors: Moreno Laura , Perez Cristina , Zabaleta Aintzane , Manrique Irene , Alignani Diego , Ajona Daniel , Blanco Laura , Lasa Marta , Maiso Patricia , Rodriguez Idoia , Garate Sonia , Jelinek Tomas , Segura Victor , Moreno Cristina , Merino Juana , Rodriguez-Otero Paula , Panizo Carlos , Prosper Felipe , San-Miguel Jesus F. , Paiva Bruno
Published: April 2023

Supplementary Figure 3
Figure S2 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Authors: Rothé Françoise , Silva Maria Joao , Venet David , Campbell Christine , Bradburry Ian , Rouas Ghizlane , de Azambuja Evandro , Maetens Marion , Fumagalli Debora , Rodrik-Outmezguine Vanessa , Di Cosimo Serena , Rosa Daniela , Chia Stephen , Wardley Andrew , Ueno Takayuki , Janni Wolfgang , Huober Jens , Baselga Jose , Piccart Martine , Loi Sherene , Sotiriou Christos , Dawson Sarah-Jane , Ignatiadis Michail
Published: April 2023

Forest plots for the test of association between ctDNA and (A) pCR or (B) event-free survival. All tests are corrected for clinic-pathological characteristics. ctDNA: circulating tumor DNA; VAF: variant allele fraction; OR: odds ratio, HR: hazard ratio; Ci: confidence interval, p: p value.
Figure S1 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Authors: Rothé Françoise , Silva Maria Joao , Venet David , Campbell Christine , Bradburry Ian , Rouas Ghizlane , de Azambuja Evandro , Maetens Marion , Fumagalli Debora , Rodrik-Outmezguine Vanessa , Di Cosimo Serena , Rosa Daniela , Chia Stephen , Wardley Andrew , Ueno Takayuki , Janni Wolfgang , Huober Jens , Baselga Jose , Piccart Martine , Loi Sherene , Sotiriou Christos , Dawson Sarah-Jane , Ignatiadis Michail
Published: April 2023

Illustration of droplet digital PCR (ddPCR)-based PIK3CA H1047L and E545K mutation detection in serial dilutions. A. Representative 1-D plot of ddPCR reactions. The ordinate scales indicate fluorescent amplitude according to FAM (6-Carboxyfluorescein) and HEX (5-hexachloro-fluorescein) fluorochromes. The magenta line represents the threshold, above which the droplets are considered positive containing at least one copy of mutated allele (blue) and below which the droplets are negative (gray) without any target DNA. Six ddPCR reactions with different serially diluted targets (%) are divided by the vertical dotted yellow lines. B. Comparison between theoretical and observed mutant concentrations.
Figure S3 from Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression
Authors: Li Xiaoming , Shepard H. Michael , Cowell Jessica A. , Zhao Chunmei , Osgood Ryan J. , Rosengren Sanna , Blouw Barbara , Garrovillo Sheryl A. , Pagel Mark D. , Whatcott Clifford J. , Han Haiyong , Von Hoff Daniel D. , Taverna Darin M. , LaBarre Michael J. , Maneval Daniel C. , Thompson Curtis B.
Published: April 2023

Reduced tumor HA via enzymatic digestion decreases HIF-1α protein expression.
Figure S2 from Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression
Authors: Li Xiaoming , Shepard H. Michael , Cowell Jessica A. , Zhao Chunmei , Osgood Ryan J. , Rosengren Sanna , Blouw Barbara , Garrovillo Sheryl A. , Pagel Mark D. , Whatcott Clifford J. , Han Haiyong , Von Hoff Daniel D. , Taverna Darin M. , LaBarre Michael J. , Maneval Daniel C. , Thompson Curtis B.
Published: April 2023

PEGPH20-mediated HA degradation increases tumor vascular area and decreases tumor hypoxia in HA-accumulating tumors.